Intrommune Therapeutics

11:00 AM - 11:15 AM (PDT), Tuesday, June 14, 2022
Intrommune Therapeutics is developing safe and effective options for individuals suffering with food allergy so that they and their loved ones can live their lives without fear.

Food allergy is an immune system reaction that occurs soon after eating a certain food. Even a tiny amount of the allergy-causing food can trigger signs and symptoms such as digestive problems, hives or swollen airways. In some people, a food allergy can cause severe symptoms or even a life-threatening reaction known as anaphylaxis. People with food allergies and their loved ones live in fear. Everyone affected is anxious for a solution.

INT301 is the initial product in development by Intrommune specifically designed to help those who suffer from peanut allergy. The product is intended to significantly raise a patient’s immune threshold through daily use of OMIT toothpaste beyond what has triggered a potentially dangerous allergic reaction via accidental exposure.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
INT301 for peanut allergy
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
All
Speaker
photo
Chief Strategy Officer
Intrommune Therapeutics